Furthermore, two recent studies have tested the combination of MET inhibitor (crizotinib) with MEK inhibitors in late-stage cancer patients (of various cancer types, not selected regarding MET status) and demonstrated preliminary disease-controlling efficacy, which supported the proposed value of MET combinations as predicted by our model simulations (Aroldi et al., 2025; Gallagher et al., 2025). This evidence concerns the gene MAP2K7 and cancer.